Abstract:Primary cutaneousCD30 lymphoproliferative diseases (CD30LPDs) are the second most common form of cutaneous T-cell lymphomas (CTCLs) and represent a spectrum of disorders ranging from lymphomatoid papulosis (LyP) to primary cutaneous anaplastic largecell lymphoma (PCALCL). They are characterized by the common phenotypic hallmark of CD30 anaplastic T cells. Although LyP has a chronic course with recurrent self-healing papulonodular lesions, PCALCLmanifests as rapidly growing and ulcerating skin tumors, and .20% of patients with multifocal skin involvement die within 5 years. Despite its usual indolent clinical behavior, LyP is associated with the development of second malignant lymphoma in nearly 20% of patients, including PCALCL and mycosis fungoides (MF). Although not considered to be a CD30LPD, MF may develop CD30 T cells, especially in the setting of largecell transformation (MF-LCT), which manifests a more aggressive clinical course. The clonal relationships between LyP and PCALCL, as well as MF have been firmly established. However, the mechanisms of tumor progression of CD30LPDs remain to be elucidated. The current hypothesis focuses on the growing resistance of CD30 lymphoma cells to extrinsic inhibitory stimuli: transforming growth factor (TGF)-b receptor mutation was shown to contribute to unregulated cell growth via abrogation of TGF-b–mediated growth inhibition. Escape from CD30L/CD30 ligation–mediated growth regulation was associated with the progression to PCALCL. Meanwhile, the intrinsic oncogenic drivers in CD30 lymphoma cells during disease progression are less known. To address this critical gap, we focus on SATB1 (special AT-rich sequence–binding protein 1), an important thymocyte nuclear protein that plays a crucial role in T-cell development. Previously we reported that SATB1 deficiency was responsible for the pathogenesis of a leukemic form of CTCL-Sézary syndrome by inducing resistance to activation-induced cell death of Sézary cells. SATB1, as a chromatin organizer, binds to matrix attachment region of DNA and participates in the maintenance and compaction of chromatin. By dynamically altering the organization and epigenetic status of the chromatin, SATB1 functions as a highly pleiotropic regulator of gene expression. Ectopic SATB1 expression has

SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile.

115 SATB1 Overexpression Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with Th17 Cytokine Profile

LYMPHOID NEOPLASIA SATB 1 overexpression promotes malignant T-cell proliferation in cutaneous CD 30 1 lymphoproliferative disease by repressing p 21

SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21.

Differential SATB1 Expression Reveals Heterogeneity of Cutaneous T-Cell Lymphoma

Cd30 Expression Defines A Novel Subgroup Of Diffuse Large B-Cell Lymphoma With Favorable Prognosis And Distinct Gene Expression Signature: A Report From The International Dlbcl Rituximab-Chop Consortium Program Study

CD30 expression defines a novel subgroup of diffuse large B cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL …

Overexpression of SATB1 in laryngeal squamous cell carcinoma.

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders: a clinicopathological analysis of 5 cases

[A Clinicopathologic Study of CD30-positive Sinusoidal Large B-cell Lymphoma].

Single-cell analyses reveal novel molecular signatures and pathogenesis in cutaneous T cell lymphoma

[Clinicopathological features of primary mucosal CD30-positive T-cell lymphoproliferative disorders]

Primary cutaneous anaplastic large-cell lymphoma with 6p25.3 rearrangement exhibits a biphasic histopathologic pattern: Two case reports and literature review

Single-Cell RNA-seq Reveals Characteristics of Malignant Cells and Immune Microenvironment in Subcutaneous Panniculitis-Like T-Cell Lymphoma

Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Primary Cutaneous CD30-positive Anaplastic Large Cell Lymphoma Analysis.

Pathologic study on lymphomatoid papulosis a report of 39 cases

The clinicopathological and molecular features of sinusoidal large B-cell lymphoma

Acitretin Combined with NB‐UVB in the Treatment of Cutaneous CD30‐positive Anaplastic Large Cell Lymphoma

A pathologic study for thirty-nine cases with lymphomatoid papulosis